What’s Trending?

Libtayo has been approved for adults when curative surgery or radiation is not appropriate [...]
Thu, May 26, 2022
Source PharmaTimes
Approval provides another step forward in transforming multiple myeloma outcomes and eliminating the disease [...]
Thu, May 26, 2022
Source PharmaTimes
AstraZeneca
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults. Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine schedule of either Vaxzevria or [...]
Thu, May 26, 2022
Source WorldPharmaNews
Technology is already being used in clinical trials of new treatments for Alzheimer's and new studies will provide additional validation [...]
Wed, May 25, 2022
Source PharmaTimes
In vitro experiments will investigate the ability of SFX-01 to increase the sensitivity of cells to radiotherapy [...]
Wed, May 25, 2022
Source PharmaTimes
Pfizer
Pfizer Inc. (NYSE: PFE) today launched 'An Accord for a Healthier World.' This groundbreaking initiative aims to provide all of Pfizer's patented, high-quality medicines and vaccines available in the U.S. or the European Union on a not-for-profit basis to 1.2 billion people in 45 lower-income countries. The Accord seeks to [...]
Wed, May 25, 2022
Source WorldPharmaNews
The U.S. federal government spent an estimated $1.8 billion in Medicare funds in 2019 on drugs whose clinical benefits have yet to be confirmed by the Food and Drug Administration, a new study led by researchers from the Johns Hopkins Bloomberg School of Public Health suggests. [...]
Tue, May 24, 2022
Source WorldPharmaNews
The bottom of the ocean is full of mysteries but scientists have recently uncovered one of its best-kept secrets. For 25 years, drug hunters have been searching for the source of a natural chemical that had shown promise in initial studies for treating cancer. Now, researchers at University of Utah [...]
Mon, May 23, 2022
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews